Role of bile acids in colon carcinogenesis

Table 1 Therapeutic agents developed against colorectal cancer targeting bile acids

Therapeutic agents	Type	Mechanism	Development phase	References
UDCA	Hydrophilic BA	Secondary BAs reduction	Clinical	[96-99]
Diosgenin	Phytochemical	BAs re-absorption prevention	Preclinical	[104-106]
Cetuximab	EGFR antibody	EGFR signaling blocking	Clinical	[101]
Panitumumab	EGFR antibody	EGFR signaling blocking	Clinical	[102]
GW4064	FXR agonist	BAs synthesis inhibition	Preclinical	[81]
Anti-FGF-19	Monoclonal Ab	BAs synthesis inhibition	Preclinical	[82]
HS-1030	UDCA derivatives		Preclinical	[100]
HS-1183	UDCA derivatives		Preclinical	[100]
HS-1199	CDCA derivatives		Preclinical	[100]
HS-1200	CDCA derivatives		Preclinical	[100]
LCA-TMA1	LCA derivatives	Apoptosis induction	Preclinical	[107]
LCA-PIP1	LCA derivatives	Apoptosis induction	Preclinical	[108]

UDCA: Ursodeoxycholic acid; LCA: Lithocholic acid; EGFR: Epidermal growth factor receptor; BA: Bile acid; FGF-19: Fibroblast growth factor 19; TMA: Trimethylammonium; PIP: Piperidine.